HAE

Haemonetics Corp. 10-Q Summary

Business Context and Reporting Period

Company: Haemonetics Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 2, 1999 (Second Quarter of Fiscal Year 2000)
Business Overview: The Company designs, manufactures, and markets automated blood processing systems, including blood bank, surgical, and plasma products. It operates as a single segment. The fiscal year 2000 includes 52 weeks; the second quarter included 13 weeks.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: For the three months ended Oct 2, 1999, net revenues increased 0.6% to $68.2 million. On a constant currency basis, revenues increased 1.1%. Disposable sales grew 3.2% (4.2% constant currency), while equipment revenues declined 29.8% due to lower sales in the blood bank business in Europe.
• Profitability: Operating income decreased 7.3% to $7.3 million for the quarter, driven by a slight decline in gross margin percentage (46.4% vs 46.9%) and increased R&D expenses. However, on a constant currency basis, operating income increased 1.0%.
• Discontinued Operations: The Company completed the divestiture of its Blood Bank Management Services (BBMS) business in May 1999. The quarter included a $144,000 gain from the recovery of an excess reserve related to this divestiture.
• Cash Flow: Operating cash flow from continuing operations increased significantly to $33.1 million for the six-month period, aided by a $5.6 million decrease in accounts receivable and improved inventory turns.
• Capital Allocation: The Company repurchased 1.1 million shares of common stock for $20.6 million during the six-month period. Capital expenditures increased to $16.9 million (six months) compared to $7.7 million in the prior year.

Guidance, Outlook, and Risks

• Tax Rate: Management expects the effective tax rate to remain at 32.0% for the full fiscal year 2000, down from 35.0% in the prior year, due to lower Japanese statutory rates and foreign sales corporation benefits.
• Year 2000 (Y2K) Compliance: The Company estimates total Y2K costs at $3 million, with 95% already spent. Management believes internal systems and production equipment are compliant. A contingency plan is in place, including increased inventory levels and a shift in the fiscal third-quarter end date to December 25, 1999, to focus resources on Y2K issues.
• Euro Conversion: The Company is preparing for the Euro adoption, with a target conversion date for information systems of April 2, 2001. Costs are not expected to be material.
• Market Risks: Over two-thirds of revenues are generated outside the U.S., creating foreign exchange exposure. The Company uses forward contracts to hedge firm sales commitments. A 10% strengthening of the U.S. dollar would increase the fair value of forward contracts by $10.5 million.

Investor Verification Checklist

• Equipment Sales Trend: Verify the sustainability of the 29.8% decline in equipment revenues and its impact on future service revenue streams.
• Y2K Contingency: Confirm the status of the contingency plan and the readiness of critical external vendors, as third-party failures could disrupt operations.
• Share Repurchases: Monitor future share repurchase activity given the $20.6 million outflow in the first half of the year and its impact on liquidity.
• Discontinued Operations: Ensure no lingering liabilities or unexpected costs remain from the BBMS divestiture.
• Foreign Exchange Hedging: Review the effectiveness of hedging strategies given the significant exposure to the Euro and Japanese Yen.